Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (1929)	10/3/2007 3:26:53 PM
From: Jibacoa	Read Replies (1) \| Respond to of 3722

After doubling in price from its Aug 27 L of $4.98 to its intraday H of $9.86 on Sep 26 SNTA met with some resistance & "profit taking".<g> But it is now up for 3rd day on a roll after some positive comments from Rodman & Renshaw, which initiated coverage with a "Market Outperform" rating and a $16 price target.<g> bigcharts.marketwatch.com In Sep 2006, SNTA reported positive results from a PIIb of its STA-4783 in 81 patients with malignant melanoma, which reportedly reached its primary endpoit. A PIII is expected to start on the 4thQ with more than 600 patients at 150 cancer centers worldwide. SNTA has stated it expects to sign a partnership for STA-4783 by the end of 2007. SNTA is also developing STA-9090 and STA-9584, which are in preclinical development; and Oral CRAC ion channel inhibitor program that is in the lead optimization stage for the treatment of autoimmune diseases. Will see how SNTA handles its resistance at the $10 level. bigcharts.marketwatch.com Bernard

To: Jibacoa who wrote (1929)	2/26/2008 10:51:28 AM
From: Jibacoa	Read Replies (1) \| Respond to of 3722

CALP has continued to try finding support above the $4 level.<g> Today it is down 6.58% on moderate volume of 18,542 about 0.2x its ADV bigcharts.marketwatch.com It announced today that it entered into an agreement with AntiCancer to establish a cross-licensing relationship and end all outstanding patent litigation. CALP will acquire the right to sublicense AntiCancer's fluorescent protein optical imaging patents to third-parties, & AntiCancer will acquire the right to sublicense Caliper's optical imaging patents, in the field of fluorescent protein imaging. As previously mentioned, CALP has 4Qs of double digit improvements on revenues & on the 3rdQ (Sep) it reported on the black $0.03 vs. the loss of $0.16 in 2006. The loss for 2007 is expected around $0.14/shr vs. $0.26 in 2006 The stock trades around 1.4xBV with little LTD & has now small +CF in spite of its long Hx of losses. The insiders hold > 10% & institutions around 30%. It seems that the R/R isn't bad at present levels. The March 2002 H was $202 <g> bigcharts.marketwatch.com Bernard